• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    9/12/23 9:06:15 AM ET
    $AVTX
    $AXLA
    $COSM
    $ELUT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVTX alert in real time by email

    Gainers

    • Tenon Medical (NASDAQ:TNON) shares increased by 54.2% to $0.22 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.0 million.
    • Cosmos Health (NASDAQ:COSM) shares moved upwards by 40.4% to $1.39. The market value of their outstanding shares is at $18.1 million.
    • Avalo Therapeutics (NASDAQ:AVTX) shares increased by 39.45% to $0.12. The company's market cap stands at $2.3 million.
    • Lyra Therapeutics (NASDAQ:LYRA) shares increased by 20.32% to $5.15. The company's market cap stands at $255.1 million.
    • MoonLake (NASDAQ:MLTX) stock increased by 18.77% to $62.5. The company's market cap stands at $3.3 billion.
    • T2 Biosystems (NASDAQ:TTOO) shares rose 15.5% to $0.3. The market value of their outstanding shares is at $100.4 million.

    Losers

    • Sight Sciences (NASDAQ:SGHT) shares declined by 35.8% to $4.18 during Tuesday's pre-market session. The market value of their outstanding shares is at $203.3 million.
    • Orthofix Medical (NASDAQ:OFIX) stock fell 19.54% to $14.99. The company's market cap stands at $550.7 million.
    • Axcella Health (NASDAQ:AXLA) shares decreased by 15.35% to $0.61. The market value of their outstanding shares is at $44.6 million.
    • NovaBay Pharmaceuticals (AMEX:NBY) shares decreased by 13.32% to $0.6. The market value of their outstanding shares is at $2.5 million.
    • EUDA Health Holdings (NASDAQ:EUDA) shares fell 12.93% to $1.28. The market value of their outstanding shares is at $31.5 million.
    • Elutia (NASDAQ:ELUT) stock decreased by 12.65% to $1.1. The market value of their outstanding shares is at $17.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $AXLA
    $COSM
    $ELUT

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Orthofix Medical Inc.
    $OFIX
    1/27/2026$14.00Hold
    TD Cowen
    MoonLake Immunotherapeutics
    $MLTX
    1/15/2026$10.00Neutral → Sell
    Goldman
    MoonLake Immunotherapeutics
    $MLTX
    1/9/2026$24.00Neutral → Buy
    BTIG Research
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    MoonLake Immunotherapeutics
    $MLTX
    11/3/2025$30.00Neutral → Buy
    H.C. Wainwright
    Orthofix Medical Inc.
    $OFIX
    10/28/2025$22.00Buy
    Stifel
    More analyst ratings

    $AVTX
    $AXLA
    $COSM
    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Williamson Kevin converted options into 1,041 shares, increasing direct ownership by 2% to 43,593 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    3/5/26 4:37:46 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Legal Officer Varki Paul

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:24:17 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Strategy Officer Riley Jennifer

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:32 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $AXLA
    $COSM
    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2

    3/4/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

    SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC. Background of the Warrant As previously disclosed, the Company entered into a securities purchase agreement dated November 26, 2025 with an accredited investor for the purchase of a warrant that was immediately exercisable into up to 2,000,000 newly issued ordinary shares of the Company. The warrant was previously amended on December 16, 2025 and Januar

    3/4/26 9:10:00 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    Elutia Regains Compliance with Nasdaq Listing Requirements

    GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company is now in full compliance with all Nasdaq continued listing requirements, and Nasdaq has advised that these matters are now closed. The Company's Class A common stock will continue to be listed and traded on the Nasdaq Capital Marke

    3/4/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $AXLA
    $COSM
    $ELUT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Orthofix with a new price target

    TD Cowen initiated coverage of Orthofix with a rating of Hold and set a new price target of $14.00

    1/27/26 8:48:16 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    MoonLake Immunotherapeutics downgraded by Goldman with a new price target

    Goldman downgraded MoonLake Immunotherapeutics from Neutral to Sell and set a new price target of $10.00

    1/15/26 8:33:55 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $AXLA
    $COSM
    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Engine Capital Management, Lp bought $1,734,956 worth of shares (137,858 units at $12.59) (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    2/26/26 5:48:59 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $AVTX
    $AXLA
    $COSM
    $ELUT
    SEC Filings

    View All

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    3/5/26 4:30:37 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 10-K filed by Sight Sciences Inc.

    10-K - Sight Sciences, Inc. (0001531177) (Filer)

    3/4/26 4:19:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    3/4/26 4:08:05 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $AVTX
    $AXLA
    $COSM
    $ELUT
    Leadership Updates

    Live Leadership Updates

    View All

    Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

    GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

    3/2/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

    GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries. "Elutia isn't for everyone," said Dana Yoo, PhD, VP of Product Development. "The bar is high, and the work is hard. But

    2/18/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $AXLA
    $COSM
    $ELUT
    Financials

    Live finance-specific insights

    View All

    Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2

    3/4/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

    GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    2/25/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2025, provided full-year 2026 financial guidance and updated its three-year financial targets. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Fourth quarter reported 2025 net sales of $219.9 million, including sales from M6 artificial cervical and lumbar discs, and non-GAAP pro forma net sales of $218.6 million, excluding sales from M6 discs, representing an increase of 2% on a reported basis and 3% on a non-GAAP pr

    2/24/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $AVTX
    $AXLA
    $COSM
    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

    SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/14/24 7:48:39 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care